Prostate cancer is the most common cancer diagnosis in men, accounting for 30% of male cancers in 2025, and is the second most common cancer in men behind skin cancer, according to the American Cancer ...

Better short-term survival with apalutamide versus darolutamide, but lots of unanswered qu ...

Preclinical study findings point to new possibilities for strategies for treating metastatic TNBC patients for whom there are no specific therapies.

Metastasis-directed therapy for oligometastatic prostate cancer was associated with improved outcomes in a systematic review and meta-analysis.

Researchers at Baylor College of Medicine have uncovered a strategy that triple negative breast cancer (TNBC) cells use to boost their ability to metastasize, or spread to other organs.

The Phase 1 clinical trial, STRIKE-001 (NCT07103018), is a multi-center, open-label dose escalation of KTX-2001 monotherapy (Part A) and in combination with darolutamide, an oral, nonsteroidal ...

PSA and Ki-67 tumour markers may identify high-risk metastatic castration-sensitive prostate cancer and inform treatment ...

Recently, the research team led by Professor Jun Pang from the Department of Urology at The Seventh Affiliated Hospital of Sun Yat-sen University discovered that cyclin-dependent kinase 12 (CDK12) can ...

Despite these totals, the long-term trend in cancer mortality reflects significant progress. As of 2023, the age-adjusted cancer death rate had dropped by 34% from its peak in 1991, averting an ...

A new study from The University of Texas MD Anderson Cancer Center has found that treating prostate cancer early, before it spreads widely, can make a big difference. The research, published in The ...

A Registrational Phase 2 clinical trial has been initiated in Japan for patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC).

But an association with improved overall survival failed to reach statistical significance ...